Search clinical trials for: AZD 1981

Total 1409 results

Samsung Medical Center

Completed

Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer

Refractory Cancer

Korea, Republic of
Samsung Medical Center

Completed

Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy

Advanced Gastric Adenocarcinoma

Korea, Republic of
Samsung Medical Center

Completed

Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment

Advanced Gastric Adenocarcinoma

Korea, Republic of
Samsung Medical Center

Active, not recruiting

This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)

Gastric Adenocarcinoma | Malignant Melanoma

Korea, Republic of
Samsung Medical Center

Completed

Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment

Advanced Gastric Adenocarcinoma

Korea, Republic of
James Cleary, MD, PhD
AstraZeneca; Stand Up To Cancer; Lustgarten Foundation

Withdrawn

Adavosertib and Gemcitabine in Advanced Pancreatic

Pancreatic Cancer
Massachusetts General Hospital
United States Department of Defense; AstraZeneca

Completed

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Meningioma | Neurofibromatosis 2

United States
R-Pharm
AstraZeneca; Russian Direct Investment Fund; The Gamaleya National Center of...

Completed

Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention

COVID-19

Azerbaijan
R-Pharm
AstraZeneca; Russian Direct Investment Fund; The Gamaleya National Center of...

Completed

Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19

COVID-19

Russian Federation
University Hospital Southampton NHS Foundation...
AstraZeneca; Cancer Research UK

Completed

Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy (ProCAID)

Prostate Cancer

United Kingdom
St George Street Capital

Completed

AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19 (ARCADIA)

Covid19

Czechia, Romania, United Kingdom
Mereo BioPharma
Syneos Health

Completed

A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. (ASTRAEUS)

Emphysema | Alpha 1-Antitrypsin Deficiency | COPD

United Kingdom, Belgium, United States, Denmark, Canada, Sweden, Poland, Spain
Cancer Research UK
AstraZeneca

Completed

A Phase I Trial of AZD3965 in Patients With Advanced Cancer

Adult Solid Tumor | Burkitt Lymphoma | Diffuse Large B Cell Lymphoma

United Kingdom
AstraZeneca

Terminated

Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.

Acute Myeloid Leukaemia

United States, Australia
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers

Renal Impairment

Bulgaria
AstraZeneca

Completed

Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment

Renal Impairment

United States
University of Manchester
Cardiff University; AstraZeneca

Active, not recruiting

Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? (COPELIA)

Endometrial Neoplasms | Carcinosarcoma

United Kingdom
Se-Hoon Lee

Terminated

AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer (SUKSES-N5)

SCLC, Recurrent

Korea, Republic of
MedImmune LLC

Completed

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

NSCLC | Resectable | Early-stage

United States, Canada, Switzerland, Italy, France, Portugal, Spain
The Christie NHS Foundation Trust
Clinical Trials Unit, Manchester

Completed

Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer (MOLTO)

Ovarian Cancer

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI); GlaxoSmithKline; Merck Sharp & Dohme LLC; Nova...

Completed

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
Chul Kim
Bristol-Myers Squibb; AstraZeneca; Walter Reed National Military Medical Center; Hackensack Meridian Health

Active, not recruiting

Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Nonsmall Cell Lung Cancer | EGFR Gene Mutation

United States
AstraZeneca
Parexel

Withdrawn

Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure

Heart Failure
AstraZeneca

Completed

Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of Midazolam

Healthy Volunteers

United Kingdom
AstraZeneca
Parexel

Completed

Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers

Chronic Kidney Disease

United Kingdom
National Cancer Institute (NCI)

Terminated

A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum

Non-Metastatic Adenocarcinoma of the Rectum

United States
AstraZeneca
Parexel

Completed

A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

Metabolic Disorders | Non-alcoholic Steatohepatitis

United States
Dana-Farber Cancer Institute
AstraZeneca

Completed

CISPLATIN + AZD-1775 In Breast Cancer

Triple-negative Metastatic Breast Cancer

United States
AstraZeneca
National Institutes of Health (NIH); Eolas Therapeutics INC.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy Volunteers

Smoking Cessation

United States
AstraZeneca
Parexel

Completed

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC (ASTRIS)

Lung Cancer

Canada, Denmark, Italy, Spain, Belgium, Korea, Republic of, Brazil, China, Taiwan, Australia, Austria, United Kingdom, Sweden, Argentina, Saudi Arabia, Ireland
AstraZeneca
Parexel

Completed

AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19

COVID-19

United Kingdom
University of Birmingham

Completed

Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. (IIH:DT)

Idiopathic Intracranial Hypertension

United Kingdom
AstraZeneca

Completed

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Myelomonocytic Leukemia | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | High Risk Myelodysplastic Syndrome | Small Lymphocytic Lymphoma | B-cell Non-Hodgkin Lymphoma | Richter's Syndrome | T-cell Non-Hodgkin Lymphoma | Relapsed or Refractory...

United Kingdom, Germany, Netherlands
Thomas Jefferson University
AstraZeneca

Active, not recruiting

Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

Recurrent Breast Carcinoma | Metastatic Malignant Neoplasm in the Chest Wall

United States
Cancer Research UK
AstraZeneca

Completed

A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)

Cancer | Non Small Cell Lung Cancer

United Kingdom
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (Himalayas)

Anemia in Incident Dialysis Patients

Russian Federation, Bulgaria, Thailand, United States, Argentina, Chile, Colombia, Korea, Republic of, Latvia, Malaysia, Mexico, Poland, Romania, Taiwan, Ukraine
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

CKD Anemia

United States, Australia, Thailand, Korea, Republic of, Malaysia, Mexico, Taiwan, New Zealand, Argentina, Chile, Colombia, Hong Kong, Peru, Philippines, Puerto Rico, Singapore
AstraZeneca
Covance; Iqvia Pty Ltd

Withdrawn

AZD1222 Vaccine for the Prevention of COVID-19

COVID-19

Russian Federation
AstraZeneca
Parexel

Completed

Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy Volunteers

Heart Failure

Germany
Soroka University Medical Center

Active, not recruiting

Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases

Lung Cancer

Israel
AstraZeneca

Completed

PET Study to Determine Muscarinic Receptor Occupancy in Lungs After Inhalation of AZD2115 and Tiotropium

Healthy Volunteers

Sweden
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects (PK)

Breast Cancer

United States
AstraZeneca
Parexel

Terminated

Evaluation of AZD8154 Concentrations in Blood

Asthma

Germany
Samsung Medical Center

Active, not recruiting

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS

Non-Small Cell Lung Cancer With EGFR T790M Mutation | With Brain and/or Leptomeningeal Metastasis | Failed Tyrosine Kinase Inhibitors

Korea, Republic of
Scynexis, Inc.

Completed

Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis (DOVE)

Candida Vulvovaginitis

United States
AstraZeneca

Completed

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

Head and Neck Squamous Cell Carcinoma

Taiwan, United States, France
AstraZeneca

Completed

AZD8601 Study in CABG Patients

Heart Failure

Finland, Netherlands, Germany
The Netherlands Cancer Institute

Completed

Olaparib and Radiotherapy in Inoperable Breast Cancer

Locally Advanced Malignant Neoplasm | Triple-Negative Invasive Breast Carcinoma | Inflammatory Breast Carcinoma

Netherlands
Chonnam National University Hospital

Completed

Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA (LiquidLung-O)

Lung Neoplasms | EGFR Gene Mutations

Korea, Republic of
National Cancer Institute (NCI)

Completed

AZD1775 for Advanced Solid Tumors

Solid Tumors

United States

Search clinical trials for: AZD 1981

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations